*October 2020*
— Similar survival and less cognitive decline compared with conventional WBRT
Stereotactic radiosurgery (SRS) for cancer patients with four to 15 brain metastases staved off cognitive decline better than conventional whole-brain radiation therapy (WBRT), while yielding similar survival outcomes, a randomized trial found.
For the primary endpoint of memory function at 4 months, patients in the SRS group had an average z-score increase of 0.21 from baseline (standard deviation [SD] 1.15) on the Hopkins Verbal Learning Test-Revised Total Recall, as compared to a decline of 0.74 (SD 1.31) in the WBRT-treated group (P=0.041), reported Jing Li, MD, PhD, of MD Anderson Cancer Center in Houston. Read more.
